Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. (2nd November 2019)

• Record Type: Journal Article
• Authors: Xie, Wei; Forveille, Sabrina; Iribarren, Kristina; Sauvat, Allan; Senovilla, Laura; Wang, Yan; Humeau, Juliette; Perez-Lanzon, Maria; Zhou, Heng; Martínez-Leal, Juan F.; Kroemer, Guido; Kepp, Oliver
• Is Part Of: Oncoimmunology. Volume 8:Number 11(2019)
• Publication Date: 2019-11-02
• Subjects: Anticancer immunity -- immunogenic cell death -- checkpoint blockade -- tumor clearance; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1656502
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Systemic treatment with the active transcription inhibitor lurbinectedin aims at inducing tumor cell death in hyperproliferative neoplasms. Here we show that cell death induced by lurbinectedin reinstates and enhances systemic anticancer immune responses. Lurbinectedin treatment showed traits of immunogenic cell death, including the exposure of calreticulin, the release of ATP, the exodus of high mobility group box 1 (HMGB1) and type 1 interferon responses in vitro . Lurbinectedin treated cells induced antitumor immunity when injected into immunocompetent animals and treatment of transplanted fibrosarcomas reduced tumor growth in immunocompetent yet not in immunodeficient hosts. Anticancer effects resulting from lurbinectedin treatment were boosted in combination with PD-1 and CTLA-4 double immune checkpoint blockade (ICB), and lurbinectedin combined with double ICB exhibited strong antineoplastic effects. Cured animals exhibited long term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors underlining the potency of combination therapy with lurbinectedin.